CSL Ltd. | Balance Sheet

Fiscal year is July-June. All values AUD Millions.
2014
2015
2016
2017
2018
Cash & Short Term Investments
645
728
748
1,101
1,103
Total Accounts Receivable
969
1,274
1,402
1,452
1,857
Inventories
1,742
2,284
2,890
3,358
3,645
Other Current Assets
41
59
87
89
154
Total Current Assets
3,398
4,344
5,128
6,000
6,759
Net Property, Plant & Equipment
1,940
2,396
3,209
3,836
4,807
Total Investments and Advances
1
1
4
5
8
Long-Term Note Receivable
-
-
-
22
21
Intangible Assets
979
1,206
1,266
1,376
2,440
Other Assets
16
24
28
7
6
Total Assets
6,651
8,328
10,157
11,893
14,583
ST Debt & Current Portion LT Debt
6
4
84
160
305
Accounts Payable
227
335
408
520
565
Income Tax Payable
121
187
278
264
336
Other Current Liabilities
542
691
1,076
1,166
1,385
Total Current Liabilities
896
1,218
1,846
2,110
2,591
Long-Term Debt
1,997
2,963
4,138
5,023
5,631
Provision for Risks & Charges
209
329
493
376
354
Deferred Taxes
182
177
362
467
281
Other Liabilities
21
22
25
34
171
Total Liabilities
3,258
4,713
6,662
7,722
9,010
Common Equity (Total)
3,350
3,574
3,448
4,125
5,522
Total Shareholders' Equity
3,350
3,574
3,448
4,125
5,522
Total Equity
3,350
3,574
3,448
4,125
5,522
Liabilities & Shareholders' Equity
6,651
8,328
10,157
11,893
14,583
Non-Equity Reserves
43
42
47
47
51

About CSL

View Profile
Address
45 Poplar Road
Parkville Victoria (VIC) 3052
Australia
Employees -
Website http://www.csl.com.au
Updated 07/08/2019
CSL Ltd. is a biopharmaceutical company, which engages in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma-derived and recombinant products, and operates plasma collection networks through CSL Plasma.